Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHA) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to 907.14%.

  • Innate Pharma's EBITDA Margin fell 5898400.0% to 907.14% in Q2 2025 from the same period last year, while for Jun 2025 it was 145.06%, marking a year-over-year decrease of 1448700.0%. This contributed to the annual value of 256.32% for FY2024, which is 2357700.0% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's EBITDA Margin is 907.14%, which was down 5898400.0% from 391.94% recorded in Q4 2024.
  • Innate Pharma's EBITDA Margin's 5-year high stood at 0.12% during Q4 2022, with a 5-year trough of 907.14% in Q2 2025.
  • Moreover, its 5-year median value for EBITDA Margin was 317.29% (2024), whereas its average is 286.81%.
  • In the last 5 years, Innate Pharma's EBITDA Margin skyrocketed by 3753600bps in 2022 and then crashed by -5898400bps in 2025.
  • Over the past 5 years, Innate Pharma's EBITDA Margin (Quarter) stood at 375.48% in 2021, then soared by 100bps to 0.12% in 2022, then crashed by -12374bps to 14.59% in 2023, then crashed by -2587bps to 391.94% in 2024, then plummeted by -131bps to 907.14% in 2025.
  • Its EBITDA Margin stands at 907.14% for Q2 2025, versus 391.94% for Q4 2024 and 317.29% for Q2 2024.